PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-16-1297
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-Like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors

Cancer Cell
Cancer ResearchOncologyCell Biology
2018English

Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition

Cancer Research
Cancer ResearchOncology
2019English

Bromodomain and Extraterminal (BET) Proteins Regulate Biliary-Driven Liver Regeneration

Journal of Hepatology
Hepatology
2016English

BET Bromodomain Proteins Are Therapeutic Targets in CRPC

Cancer Discovery
Oncology
2014English

Alveolar Rhabdomyosarcoma–associated PAX3-FOXO1 Promotes Tumorigenesis via Hippo Pathway Suppression

Journal of Clinical Investigation
Medicine
2013English

Alveolar Rhabdomyosarcoma – The Molecular Drivers of PAX3/7-FOXO1-induced Tumorigenesis

Skeletal Muscle
OrthopedicsSports MedicineCell BiologyMolecular Biology
2012English

Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-Terminal Domain (BET) Proteins

English

Insulin and LiCl Synergistically Rescue Myogenic Differentiation of FoxO1 Over-Expressed Myoblasts

PLoS ONE
Multidisciplinary
2014English

BET Bromodomain Inhibitors Synergize With ATR Inhibitors in Melanoma in Melanoma

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy